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Abstract 
Efficient syntheses of the three N-alkylated analogues of the known PPARδ antagonist 
GSK3787 were investigated. In this thesis the analogues; N-methyl-N-(2-((5-(trifluoromethyl) 
pyridine-2-yl)sulfonyl)ethyl)-2-naphtamide (11), N-ethyl-N-(2-((5-(trifluoromethyl)pyridine-
2-yl)sulfonyl)ethyl)-2-naphtamide (13) and N-benzyl-N-(2-((5-(trifluoromethyl)pyridine-2-
yl)sulfonyl)ethyl)-2-naphtamide (15) were achieved. An additional preparation of 15 was 
developed and showed to be a convenient alternative to the first route. 
 
Based on previous work performed on the PPARδ antagonist GSK3787 and analogues, we 
anticipate that the three compounds 11, 13 and 15 will be potent and selective PPARδ 
antagonists.  
 
Biological evaluations of all new potential PPARδ antagonists will be conducted in the near 
future. 
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AF-1 activation function 1 
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PPAR peroxisome proliferator-activated receptor 
RE response element 
RXR retinoid X receptor 
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T2DM type 2 diabetes mellitus 
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TZD thiazolidinedione 
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1 Introduction 
 
1.1 PPAR as a therapeutic target 
The ability of nuclear receptors to induce or repress the transcription of different gene 
programs renders them interesting pharmacological targets [1]. Contrary to this, the 
complexity of the transcriptional response to nuclear receptor modulation and the not yet fully 
understood mechanisms involved in the events that lead to the transcription of specific genes, 
also makes them problematic targets to work with [2]. Since the discovery of the peroxisome 
proliferator-activated receptors (PPARs) in the 1990s, several studies have been undertaken to 
elucidate their biological roles and structural features. The functions of PPARs are 
widespread; from cell-cycle control, to metabolism and energy homeostasis, the latter having 
been the main function of interest in the context of PPARs as therapeutic targets [1, 2]. 
 
1.1.1 Metabolic disorders 
Overweight has in the last decade become a major health problem among people in developed 
countries. In 2007, the proportion of people that suffered from clinical obesity (BMI ≥ 30) 
exceeded 30% of the adult population in the USA [3]. In 2008, WHO estimated the number of 
overweight people to be 1.4 billion on world basis [4]. A number of severe physiological 
malfunctions are associated with this condition. Metabolic syndrome, with its risks of type 2 
diabetes mellitus (T2DM) and cardiovascular disease, is one of the main concerns. Metabolic 
syndrome is a condition characterized by abdominal obesity, hyperinsulinemia, dyslipidemia 
and hypertension [5]. 
 
The glucose-homeostasis is held in control by insulin, a hormone secreted from the β-cells in 
the pancreas. Insulin increases glucose uptake by peripheral cells (mainly muscle and adipose 
tissue) and is secreted in response to high levels of blood glucose. In the liver insulin inhibits 
gluconeogenesis. In obese persons, the normal secretion of insulin may become disrupted, due 
to the responding cells gaining resistance against insulin, which results in continuous high 
levels of blood glucose. This will make the β-cells compensate by secreting more insulin, 
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resulting in hyperinsulinemia. If this situation persists over time, it may ultimately lead to 
total insulin resistance and dysfunctional β-cells [6]. 
 
Obese persons also tend to have a non-satisfactory lipid profile [7]. Lipids and cholesterol are 
transported in the bloodstream in complexes known as lipoproteins. There are four main 
classes of lipoproteins, each with a specific role in the transport of lipids. Chylomicrons 
transport intestinally absorbed triglycerides and cholesterol via the bloodstream to the tissues, 
where the triglycerides are split by lipoprotein lipases, releasing free fatty acids to muscle and 
adipose tissue. The remnants of the chylomicrons, including cholesterol, are taken up by the 
liver, stored here or converted into very low-density lipoprotein (VLDL). VLDL transports 
cholesterol and newly synthesized triglycerides from the liver to peripheral tissues, where 
they release the triglycerides as before and become low-density lipoprotein (LDL), a 
lipoprotein with a large proportion of cholesterol. Some LDL remains in the tissues and some 
is taken up again by the liver. Another lipoprotein class, high-density lipoprotein (HDL), 
reverses the transport, by absorbing cholesterol derived from cell breakdown in tissues and 
arteries, and transferring it to VLDL and LDL. It is favourable to have a high proportion of 
HDL compared to VLDL/LDL. However, in obese persons, the HDL level is decreased and 
VLDL and LDL levels are increased. This is known as dyslipidemia [8]. 
 
Both insulin resistance and dyslipidemia result in elevated blood glucose levels and 
hypertension, and if not controlled at an early stage, to T2DM. In fact, 80% of people with 
T2DM suffer from overweight [9]. These metabolic disruptions, all together as in metabolic 
syndrome, or individually, elevate the risk of developing potentially fatal conditions like 
atherosclerosis, ischemic heart disease and severe T2DM [10]. 
 
1.1.2 Current treatment of metabolic syndrome 
The most effective treatment of the disorders involved in metabolic syndrome involves 
lifestyle modifications. Reducing weight, increasing the amount of exercise and lowering 
dietary fats and glucose, are all beneficial factors to prevent the development of metabolic 
syndrome [11]. For patients, these lifestyle changes often tend to be difficult to comply with 
and pharmaceutical intervention seems to be necessary in most cases. Employing the drugs 
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currently on the marked, the treatment of metabolic syndrome combines lipid-modifying and 
antihypertensive drugs, with insulin sensitizers and other blood glucose-lowering drugs. The 
efficacy of this therapy is varying among individuals. The side-effects of the currently 
available treatments are often a problem, and given the need for life-time treatment, they 
become important limiting factors [12, 13]. 
 
PPARs are one of the main receptor families involved in energy homeostasis and thus, 
targeting these receptors have, for obvious reasons, gained much interest the recent years [14]. 
The need for further studies on how nuclear receptors like PPARs control gene transcription is 
necessary, in order to develop more efficient and safe drugs than those currently on the 
marked. To gain the knowledge required, the development of PPAR-selective modulators is 
of interest [15]. 
 
1.2 PPAR biology 
 
1.2.1 Nuclear receptors and classification of PPARs 
Nuclear receptors are a family of ligand-activated transcriptions factors that regulate gene 
transcription by binding to specific regions in the target DNA called response elements (REs). 
They can be classified according to the organization of their REs and dimerization properties. 
The class I nuclear receptors include the steroid receptors (the estrogen receptor, androgen 
receptor and mineralocorticoid receptor) and are located in the cytoplasm. They bind as 
homodimers to the REs upon activation by hormones.  The class II nuclear receptors include 
the endocrine receptors (such as the thyroid hormone receptor and retinoic acid receptor) and 
bind to the REs as heterodimers with the retinoic X receptor (RXR). In the absence of ligands, 
these receptors are found inside the nucleus in association with corepressor proteins that 
inhibit transcriptional activity. The binding of ligands results in release of the corepressors 
and binding of coactivators, that in turn initiates the transcription of target genes. The class III 
nuclear receptors comprise mostly orphan receptors, for which no respective endogenous 
ligands have been identified to date. [16]. 
 
4 
The PPARs remained orphan receptors for a long time, but due to the discovery of fatty acids 
and eicosanoids as their endogenous ligands, in addition to current knowledge about their 
binding to DNA as heterodimers with the RXR (Figure 1.1), they are now included in the 
class II of nuclear receptors [1, 5, 12]. 
 
 
Figure 1.1: Mechanism of PPAR-induced gene transcription (copied from Kota et al., 2005 [1]). 
 
1.2.2 Structural features of the PPARs 
The nuclear receptors share similar structural characteristics and contain four functional 
domains, named A/B, C, D and E/F, in addition to activation function 1 (AF-1) and activation 
function 2 (AF-2) (Figure 1.2). 
 
Figure 1.2: Functional domains of the nuclear receptors [1]. 
 
The A/B domain hosts the ligand independent AF-1 and is an identified site of 
phosphorylation of the PPARs. This N-terminal domain is highly conserved among the 
nuclear receptors. The C domain is the region that binds to DNA and recognizes the PPAR-
specific response elements (PPREs) in the promoter regions of the target genes. The D 
domain, together with AF-2 binds coregulator proteins. The E/F domain contains the ligand 
binding domain (LBD), which is specific to each receptor class and/or subtype [1, 8]. To date, 
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there are three identified subtypes of PPARs, named α, β/δ and γ, distinguished by differences 
in their LBDs [16]. The ligand binding pocket of the LBD is defined by 34 amino-acid 
residues, of which about 80% are homologous between the PPAR [17]. 
 
1.2.3 Endogenous ligands 
PPARs are lipid-sensing receptors which mean that they are activated by fatty acids and fatty 
acid metabolites. Long chain fatty acids (e.g. palmitic acid, oleic acid, linoleic acid and 
arachidonic acid), various prostaglandins and leukotrienes, have all been shown to be 
endogenous activators of PPARs (Figure 1.3). The affinities of these PPAR ligands are in the 
µM-range. Because of uncertainty about whether the free concentrations of these fatty acids in 
cells become high enough to activate the receptor, it is proposed that one function of PPARs 
is to be a measure of the total flux of fatty-acids in metabolically active tissues, rather than 
being highly ligand-specific receptors [18]. On the other hand, nitrooleic acid, a nitro 
derivative of the unsaturated oleic acid, has been reported to activate PPAR, more specific 
PPARγ, with high affinity (nM-range). Nitro derivatives are endogenous products of NO˙ and 
NO2
-
 mediated redox processes in the body and levels of free nitrooleic acid have been 
detected in 1–3 nM in human plasma [19].  
 
Figure 1.3: Structure of some endogenous ligands of the PPARs [19, 20]. 
 
1.2.4 Distribution and primary biological functions of PPARs 
The three known PPAR subtypes have different tissue distributions in the body, overlapping 
each other to some extent (Table 1) [21]. 
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Table 1: Tissue distributions of the PPAR subtypes in humans [21]. 
PPAR-subtype Mainly found in Also found in 
α Liver, brown adipose tissue Heart, kidney, muscle 
γ Adipose tissue Intestine, macrophages 
β/δ Heart, muscle Skin, brain, adipose tissue 
 
PPARα is expressed in tissues with high mitochondrial and peroxisomal activity, such as the 
liver and brown adipose tissue, where it is essential to maintain the lipid homeostasis. In the 
liver, PPARα stimulates fatty acid catabolism and gluconeogenesis. It has also been shown to 
increase the level of apolipoprotein A1 (a component of HDL) and decrease apolipoprotein 
CIII-level (a component of VLDL), thus modulating the lipid profile. The expression of fatty-
acid transport proteins (FATP and FAT) is increased upon PPARα activation, resulting in 
improved cellular uptake of circulating fatty acids [1]. 
 
PPARγ is found as two different isoforms, γ-1 and γ-2. PPARγ-2 is expressed almost 
exclusively in adipose tissue, whereas PPARγ-1 is ubiquitously expressed. PPARγ is essential 
for adipocyte differentiation and survival, and it plays an important role in lipogenesis [22]. 
PPARγ improves insulin sensitivity by controlling various adipokines involved in the 
development of insulin resistance, but also by having beneficial effects on the glucose 
homeostasis [12]. Anti-inflammatory effects have also been reported [12]. 
 
PPARδ is ubiquitously expressed and its effects are similar to PPARα, in that it increases lipid 
metabolism and energy uncoupling. While PPARα exerts its action mainly in the liver, 
PPARδ is found in higher levels in heart and skeletal muscle, especially in oxidative muscle 
fibers. PPARδ activation has beneficial effects on the lipid profile and represses hepatic 
glucose output [23]. 
 
1.2.5 Synthetic ligands in clinical use 
Two classes of compounds that target PPAR have reached the marked so far; the fibrates and 
the thiazolidinediones (TZDs). 
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The fibrates (e.g. gemfibrozil and fenofibrate, Figure 1.4), target the PPARα subtype and 
improve lipid profile and glucose-tolerance. Although they have been on the marked in 
European countries since 1960, the European Medicines Agency (EMA) concluded in 2005 
that documentation of long-term efficacy in reducing cardiovascular disease in human was 
poor, compared to the alternative lipid-lowering drugs. EMA thus recommended that fibrates 
should not be used as first-line treatment, except in rare cases where other available drugs 
(such as statins) are not tolerated or in cases of severe hypertriglyceridemia. None of the 
fibrates are currently on the regular market in Norway [24]. 
 
Figure 1.4: Structure of two fibrates that target PPARα [25]. 
 
The TZDs target the PPARγ subtype and are insulin sensitizing drugs that lower blood 
glucose, with additional positive effects on plasma triglycerides and HDL cholesterol. In 
Norway, the only TZD on the marked is pioglitazone (Actos
TM
), and side effects are limiting 
its use. Pioglitazone may cause retention of body fluids and oedema, which can be detrimental 
to individuals with reduced cardiac function. Induction of lipogenesis, resulting in gain of 
weight, is another disadvantageous effect of TZDs [13, 26].  
 
Figure 1.5: Structures of two drugs in the TZDs class that target PPARγ. They are both sold as racemates. 
[26]. 
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1.3 The role of PPARδ as a therapautic target 
 
1.3.1 Discovery of PPARδ ligands 
PPARδ was the last of the PPAR subtypes to be identified and for a long time, the knowledge 
about its biological role was limited due to its broad tissue distribution and lack of a potent 
and highly selective ligand. Over the past several years, this has changed dramatically. In 
2003, two synthetic ligands, GW501516 and GW0742, were reported by GlaxoSmithKline. 
The compounds showed agonistic activities, high affinity (~ 1 nM) and more than 1000-fold 
selectivity for PPARδ compared to the other subtypes. This was an important contribution to 
the study of the biological functions of PPARδ [27]. 
 
Figure 1.6: The PPARδ agonists GW501516 and GW0742 [27]. 
 
No drug targeting PPARδ is currently in clinical use, but with growing evidence for the 
beneficial effects the activation of this subtype has on various metabolic parameters, its 
potential as a therapeutic target is of great interest [28]. 
 
1.3.2 Beneficial metabolic effects of PPARδ agonism 
Skeletal muscles consist of different fiber types with distinct metabolic profiles: oxidative 
slow-twitch (Type I), mixed oxidative/glycolytic fast-twitch (Type IIa) and glycolytic fast-
twitch (Type IIb). Oxidative muscle fibers generally express enzymes that oxidize fatty acids 
whereas glycolytic fibers preferentially use glucose as energy source [21]. 
 
PPARδ is highly expressed in oxidative muscle fibers [23]. Animal models overexpressing 
PPARδ has shown a change in fiber composition in muscle, due to both increased production 
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of and switch to a more oxidative muscle fiber type. The animals showed a leaner phenotype, 
greater enzymatic activity and increased expression of genes related to oxidative metabolism 
[29]. Transgenic mouse overexpressing PPARδ in skeletal muscle, show a decrease in body 
fat content related to reduced adipocyte size and an increased proportion of oxidative slow 
twitch fibers [30]. Several studies in humans confirm impaired fat oxidation in obese 
phenotypes. Improving the fat oxidation potential, especially that of muscle and adipose 
tissue, may have positive effects on weight loss [12]. Slow-twitch fibers also show a greater 
extent of insulin stimulated glucose transport than do fast-twitch fibers, and the body’s insulin 
sensitivity seems to be positively correlated with the proportion of slow-twitch fibers. It is 
proposed that PPARδ activation have a protective effect against obesity and insulin resistance 
[21]. 
 
Studies in insulin resistant obese monkeys show that PPARδ agonism has a beneficial effect 
on the lipid profile, by raising HDL cholesterol and lowering LDL cholesterol, triglycerides 
and fasting insulin levels [5]. In vivo studies in obese, diabetic db/db mice, shows that 
treatment with PPARδ agonists increases HDL cholesterol, with no effect on LDL cholesterol 
[31]. In addition, PPARδ was shown to regulate the levels of serum triglycerides in mice, by 
reducing VLDL production and increasing lipoprotein lipase activity on VLDL triglycerides 
[32]. 
 
1.3.3 PPARδ antagonism 
The use of PPARδ agonists in combination with knockout models, have shown that the above 
mentioned effects are indeed PPARδ receptor mediated. Much effort has been put into the 
development of PPARδ agonists and their contribution to a better understanding of the effects 
of PPARδ agonism has been valuable. 
 
Lately, the development of PPARδ antagonists has received more attention. Ligand mediated 
repression of the PPARδ gene program provides a valuable tool for elucidating the receptor’s 
role in human biology. Furthermore, beneficial pharmacological effects of antagonists are 
observed, making them potential leads for drug development. For instance, PPARδ 
antagonists have been reported to inhibit cancer cell invasion by repressing ANGPTL4 
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induction in a study on human breast cancer cells [33]. In another study PPARδ antagonism 
inhibits tumor proliferation and survival of liver, breast and lung cancer cells, linked to G1/S 
cell cycle block and increased apoptosis [34]. Despite of these findings, there are 
controversial results from other studies related to PPARδ and cancer, confirming the need for 
further identification of the cellular mechanisms involved. Increased knowledge about PPARδ 
antagonism may also contribute to a better mechanistic understanding of the transcriptional 
control of nuclear receptors in general, given the similarities between receptors in this family 
[16]. Development of new PPARδ antagonists is thus warranted.  
 
1.4 Previously reported PPARδ antagonists  
 
1.4.1  The GSK0660-series 
The first PPARδ antagonist, GSK0660, was reported by researchers at GlaxoSmithKline in 
2007 (Figure 1.7, R = Ph). It is highly selective towards PPARδ and displays an IC50 ~160 
nM. At higher concentrations, GSK0660 can completely inhibit both the agonist-induced 
expression as well as the basal expression of PPARδ target genes, such as ANGPTL4 and 
CPT1a [35]. Unfortunately, lack of oral bioavailability of GSK0660 limits its usage in studies 
in vivo [36]. Recently, Müller et al., developed a series of compounds analogues to GSK0660, 
of which the compound with R = n-Bu displayed a 10-fold higher binding affinity than 
GSK0660 (Figure 1.7) [37, 38]. 
 
R-group IC50 (nM) Ki (nM) Name 
n-Bu -  8.59  - 
t-Bu  98  - PT-S58 
n-Hex  93  - ST247 
i-Pent -  12.10  - 
Ph  160   98.15  GSK0660 
Bn -  12.34  - 
 
Figure 1.7: Structure of GSK0660 (R = Ph) and analogues, developed by Müller et al. [35, 37, 38]. 
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1.4.2 DG172 
The same research group, Müller et al., recently reported a structurally distinct PPARδ 
antagonist, named DG172 (IC50 = 26.9 nM). It has an electrophile acrylonitrile moiety, which 
was found to be crucial for its activity (Figure 1.8) [39]. 
 
Figure 1.8: Structure of the PPARδ antagonist DG172 [39]. 
 
1.4.3 Carboxylic acid containing PPARδ antagonists 
SR13904 is an antagonist reported by Zaveri et al. in 2009 (Figure 1.9). Surprisingly, this 
compound features a carboxylic acid head group, in analogy to prototypical PPAR agonists. 
The compound was reported to have anti-tumor activity, by inhibition of cancer cell 
proliferation and increased apoptosis [34]. A series of related compounds were reported by 
Kasuga et al. the same year. These compounds also contain carboxylic acid head groups and 
are analogues to TIPP-204, a highly potent, PPARδ selective agonist, also developed by 
Kasuga et al.[40] (Figure 1.9). For the latter series, the authors hypothesize that the length and 
rigidity of the head group induces a misfolding of helix 12 located in the AF-2, the correct 
folding of which is aided by the carboxylic acid head groups of prototypical PPAR-agonists 
[40]. 
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Figure 1.9: Structures of two PPARδ antagonists containing carboxylic acid head groups, and the agonist 
TIPP-204, for comparison [34, 40]. 
 
1.4.4 The GSK3787-series 
Another structurally distinct PPARδ antagonist, identified during high-throughput screening 
at GlaxoSmithKline, is GSK3787 (Figure 1.10). This compound is selective for the δ-subtype 
and antagonizes 100% of the agonist-induced expression of two PPARδ target genes, CPT1a 
and PDK4, when coadministered with the full PPARδ agonist GW0742. When tested alone, it 
acted as an inverse agonist, repressing the basal level of CPT1a expression, but not that of 
PDK4 [36]. 
 
Figure 1.10: Structure of the PPARδ antagonist, GSK3787, and selected structural features [36]. 
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A structure-activity relationship (SAR) study was performed by Shearer et al. on a series of 
analogues of GSK3787 to identify the pharmacophore. This established some structural 
features important for the activity: [36]. 
 
- The length of the aliphatic linker; both a 1- and a 3-carbon lenghts showed reduced 
activity, indicating that a 2-carbon chain was the most suited linker length.  
- The substituent on the pyridine ring; a trifluoromethyl group gave an active 
compound, whereas a hydrogen or a methyl group afforded inactive compounds. 
- A sulfide in the place of the sulfone resulted in an inactive compound. 
- Substitution of the arylamide ring with a trifluoromethoxy group, bulky lipophilic 
groups or disubtitution, gave minor changes in activity.  
Taken together, these results indicate that a strong electron withdrawing group para to the 
sulfone and a 2-carbon chain separating the aromatic rings is important (Figure 1.10) [36]. 
 
Shearer et al. performed mass spectrometrical analysis of the binding of GSK3787 and an 
analogue of different molecular weight, featuring the same pyridylsulfone moiety, to PPARδ. 
They found that both compounds covalently modified Cysteine (Cys249) with the same 5-
trifluoromethylpyridyl fragment. Shearer et al. proposed a mechanism that possibly involves 
the nucleophilic attack of the thiol in Cys249 with the carbon in 2-position on the pyridine 
ring, displacing the sulfone group as a sulphinate (Figure 1.11) [36]. 
 
Figure 1.11: Proposed mechanism for covalent binding of GSK3787 analogues by Shearer et al. [36]. 
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1.4.5 Previous work on PPARδ antagonists at The Department of 
Pharmaceutical Chemistry, School of Pharmacy, Oslo 
Our research group has lately focused on the molecular modeling and synthesis of analogues 
of GSK3787 [20, 41, 42]. A compound named CC618 (Figure 1.12) was prepared by Dr. 
Calin C. Steindal (né Ciocoiu), which inhibited agonist-induced oleic acid oxidation in a cell-
based assay, suggesting its antagonistic activity. Moreover, an IC50 = 0.9 µM was observed, 
thus making it slightly more potent than GSK3787 (IC50 = 3 µM in the same assay). Docking 
of the compound into the LBD of PPARδ indicated high affinity for the receptor [20, 42]. 
 
Figure 1.12: Structure of the prepared PPARδ antagonist CC618 [20, 42]. 
 
In 2012, a series of analogues of GSK3787 were synthesized by a master student, Cecilie 
Xuan Trang Vo [41], in which she introduced variations in the arylamide moiety, but also 
made one analogue containing an N-methyl substituent (Figure 1.13). 
 
Figure 1.13: GSK3787 analogues previously synthesized by Cecilie Xuan Trang Vo [41]. 
 
Later the same year, Ph. D. student Åsmund Kaupang, performed molecular modeling studies 
on GSK3787 analogues. A series of analogues of GSK3787 with variations in the arylamide 
moiety and the N-alkyl substituents, were docked into the LDB of PPARδ. A 2-naphthyl-
analogue with N-methyl substitution showed the highest docking scores of the compounds 
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submitted. Its poses in the ligand binding pocket, suggest that the sulfone group has a 
hydrogen bond to a water molecule and the electron-poor 2-carbon in the pyridine ring is 
located at a distance of 4.127 Å from the reactive cysteine residue (purple line, Figure 1.14).  
 
Figure 1.14: The lowest energy pose of the N-methyl analogue 11 docked into the LBD of PPARδ (RCSB 
PDB CODE: 3TKM) 
 
1.5 Aim of the thesis 
With a background in the results from the reported SAR study on GSK3787, previous 
syntheses of PPARδ antagonists and the results from the docking studies of a various 
analogues, into the LBD of PPARδ, the aim of this thesis was to develop an efficient route for 
making several new PPARδ- antagonists, analogues to GSK3787, with 2-naphtyl as the 
arylamide moiety and with variations in the N-alkyl substituent (Figure 1.15). 
 
 
Figure 1.15: Outline of the synthesis of the target molecules. 
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2 Results and discussion 
 
2.1 Synthesis of the N-alkylated analogues 
Since the N-methyl analogue 11 (Figure 2.1) displayed the highest score in the docking 
studies, it was decided to start with the preparation of this compound. 
 
Figure 2.1 Structure of the N-methyl analogue 11. 
 
We wanted to develop an efficient route for introducing different alkyl groups on the amide 
nitrogen. Five different approaches were explored. 
 
2.2 The first approach; direct amide N-alkylation of 
the sulfone 7 
A previous attempt to directly N- alkylate an analogous secondary amide, using NaHMDS for 
the deprotonation of the amide, was not successful [41]. An explanation for this could be the 
acidic protons alpha to the sulfone. With only slightly higher pKa-values than the amide 
proton, they are also prone to deprotonation, that would lead to alpha-alkylation instead of N-
alkylation. 
 
With this in mind, we wanted to attempt deprotonation with t-BuOK instead, as it is a weaker 
base and hopefully a better choice to remove only the amide proton. By managing to directly 
N-alkylate the amide of sulfone 7, we would gain easy access to the target molecules from a 
common precursor (Scheme 2.1). 
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Scheme 2.1: Outline of direct N-alkylation of the sulfone 7. 
 
To investigate this possibility, we needed to make the sulfone 7 for use in the alkylation 
(Scheme 2.2). 
 
Scheme 2.2: Outline of the synthesis of the sulfone 7 needed for the first approach. 
 
The first step in the synthesis towards 7 was to prepare the intermediate 5 (Scheme 2.3), 
which in the next step could be acylated with the desired acid chlorides, according to the 
procedure previously reported by Shearer et al. [36]. 
 
Scheme 2.3: Synthesis of intermediate 5. 
 
Reacting the thiol 1 with the bromide 2 in a nucleophilic substitution reaction afforded the 
thioether 3. Oxidation of 3 to sulfone 4, in the next step, was performed using potassium 
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peroxymonosulfate triple salt (Oxone
TM
). Removal of the Boc-protection group from sulfone 
4, with HCl in dioxane, yielded the hydrochloride salt 5. 
 
The final step involved acylation of intermediate 5 with 2-naphthoyl chloride 6, to afford 7 in 
63% yield (Scheme 2.4). 
 
Scheme 2.4: The final step in the synthesis towards sulfone 7. 
 
Thus, in an attempt to prepare 11, sulfone 7 was treated with t-BuOK, followed by the 
addition of MeI in large excess (Scheme 2.5). 
 
Scheme 2.5: Attempted direct N-alkylation of compound 7. 
 
Unfortunately, the desired product could not be isolated from the complex mixture obtained 
and this route was thus abandoned. 
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2.3 The second approach; direct amide N-alkylation 
of the sulfide 9 
Next, we wanted to investigate the possibility to perform N-alkylation of the sulfide 9, rather 
than on the sulfone 7, hoping that the lack of acidic alpha-protons, would facilitate the 
alkylation of the amide nitrogen. 
 
We proceeded with the preparation of the sulphide 9. Removal of the Boc-group from the 
previosly prepared thioether 3, afforded the corresponding hydrochloride salt 8, which in turn, 
was acylated with 2-naphthoyl chloride (6) to afford 9 in moderate yields (Scheme 2.6). 
 
Scheme 2.6: Synthesis of the intermediate 9. 
 
With sulfide 9, we could successfully carry out the alkylation of the amide nitrogen with 
different alkyl halides, to afford the N-alkylated sulfides 10 (yield not determined), 12 and 14 
in moderate to good yields. In the preparation of 14, a combination of BnBr and TBAI was 
used successfully as a surrogate for the alkyl iodide. We then proceeded with oxidation of the 
sulfides with potassium peroxymonosulfate triple salt (Oxone
TM
), to the target sulfones 11, 13 
and 15 (Scheme 2.7). 
  
21 
 
Scheme 2.7: N-alkylation and oxidation of the sulfide 9, affording the analogues 11, 13 and 15. 
 
These procedures were carried out in accordance with those for the previously synthesized N-
methyl analogue of GSK3787, containing 4-fluorobenzyl in the place of 2-naphthyl (Figure 
1.13) [41]. 
 
To see if we could develop a more efficient synthesis route towards the target molecules, we 
continued to explore alternative routes. 
 
2.4 The third approach; direct amide N-alkylation of 
the carbamate 3 
We wanted to see if it was possible to alkylate the carbamate 3 directly. We carried out two 
attempts to alkylate 3 with i-PrBr in order to afford 16 (Scheme 2.8). 
 
Scheme 2.8: Outline of the third approach; alkylation of the carbamate 3. 
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The first attempt was performed in accordance with the N-alkylation step described in the 
second approach (Scheme 2.7) in which 3 reacts with excess amounts of i-PrBr, in the 
presence of NaH and TBAI. 
 
In the second attempt we based the procedure on a carbamate alkylation protocol reported by 
Salvatore et al. which employs Cs2CO3 as the base [43].  
 
Characterization of the crude material from the first attempt showed a mixture of starting 
material and possibly small amounts of the desired N-propylated sulfide 16. The yields were 
not improved compared to the second approach (direct amide N-alkylation of the sulfide 9). In 
the second attempt, a TLC of the reaction after 5 days, showed very low conversion of the 
starting material, and the approach was thus abandoned. 
 
2.5 The fourth approach; the reductive amination 
route 
 
An alternative way of introducing an N-alkyl substituent in the target molecules was explored 
(Scheme 2.9). By performing a reductive amination we could maintain control of the N-alkyl 
group, and avoid the problems with the alkylation of an amide, a reaction that can be difficult 
due to the unreactivity of the amide nitrogen in general [44]. This reductive amination route 
would afford the desired N-alkylated compounds, but would also serve as a convergent route 
for making analogues with different arylamide moieties. 
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Scheme 2.9: Outline of the reactions in the fourth approach; an alternative route involving reductive 
amination. 
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By reacting etanolamine (17) with benzaldehyde (18) in methanol, followed by addition of 
NaBH4, we were able to obtain 2-(benzylamino)ethanol (19) in 66% yields, according to a 
procedure reported by Jiang et al. [45]. The addition of different aldehydes in place of 
benzaldehyde, different N-alkyl subtituents could have been achieved. 
 
Boc-proctection of 2-(benzylamino)ethanol (19) to 20 with Boc2O proceeded in excellent 
yields (93%). 
 
Next, we wanted to substitute the OH-group in 20. Our first attempt employed an Appel 
reaction, according to a reported procedure by Baughmann et al. [46]. By reacting 20 with 
PPh3 and CBr4 in CH2Cl2, in the presence of pyridine, we could obtain the bromide 21 that 
could react with the thiol 1, in the next step, in analogy to the preparation of sulfide 3. This 
would afford sulfide 23. First, we did an attempt to purify and isolate the bromide 21, which 
turned out to be difficult due to the compound’s invisibility upon TLC analysis. Second, we 
did an attempt on bromination without purification of the bromide 21, and with addition of the 
thiol 1 to the crude product from the bromination. 
1
H NMR analysis of the product showed 
significant amounts of PPh3O, and made it less convenient to proceed to the next step. 
 
Instead we decided to make a mesylate of the OH-group of 20, by adding MsCl and Et3N in 
CH2Cl2, followed by the addition of thiol 1, in order to afford 23. Unfortunately, we obtained 
low yields (4%). One possible explanation of this may be the instability of the mesylate 22, 
which likely should be used immediately after preparation. In this case, 22 was used the day 
after preparation. A TLC analysis of the mesylate 22 after employing it in the reaction, 
showed an additional spot, probably due to decomposition of the mesylate back to the alcohol 
20. We therefore decided to attempt a second mesylation, directly followed by addition of the 
thiol 1. This afforded slightly higher yields (13%) of 22. In a last attempt to improve the 
yields, we added NaI together with the other reagents to improve the reactivity in the SN2-
reaction. Unfortunately, this did not improve the yields and the route was thus abandoned. 
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2.6 The fifth approach; acylation of the N-benzyl 
HCl-salt (29) 
By this time, a Ph. D. student in the group, Åsmund Kaupang, also working on PPARδ-
antagonists, had outlined a synthesis of an N-benzyl HCl-salt 29, that could be acylated with 
2-naphthoyl chloride 6 to yield 15 directly (Scheme 2.10). 
The acylation reaction afforded 15 in good yields (84%). 
 
Scheme 2.10: Outline of the fifth approach, with acylation of the HCl-salt 29 as the final step towards 15. 
 
The synthesis of 29 was performed as outlined in Scheme 2.11 and started with the acylation 
of benzylamine (BnNH2) with bromoacetyl bromide 25, to afford the amide 26 in good yields 
(87 %). The thiol 1, was then reacted with 26 in an SN2 reaction, to afford 27 (87%). The 
amide 27 was reduced with in situ generated BH3 (LiBH4 + BF3·O(CH3)2) to the amine 28. 
Oxidation of the sulfide in 28 with aqueous H2O2 and B(OH)3  afforded the sulfone, which 
was precipitated as its hydrochloride salt 29 (30% over two steps). 
 
Scheme 2.11: Outline of the synthesis of the intermediate 29. 
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3 Conclusions and future work 
 
Five different routes towards the target molecules were explored. The synthesis of a series of 
three N-alkylated analogues 11, 13 and 15 , by two different routes. The first one was based 
on a previously reported synthesis of GSK3787 and involved the N-alkylation of sulfide 9, 
with an oxidation as the last step. This yielded all three analogues 11, 13 and 15. The 
analogue 15 was also synthesized by an alternative route, in which acylation of the N-benzyl 
HCl-salt 29 was the final step.  
 
The aim of this thesis was to develop an efficient route for making N-alkylated, 2-naphthyl-
analogues of GSK3787. The number of reaction steps, the yields and the overall ease of the 
synthesis will all be aspects to consider when comparing the two different routes. 
 
Both routes towards the prepared N-alkylated analogues included five steps, with the overall 
yield from the first route being slightly higher than that of the second - 31% vs. 19% for the 
preparation of 15. In the second route the key intermediate 29 were precipitated as its 
hydrochloride salt, thus reducing the number of steps requiring time-consuming preparative 
chromatography to two, compared to four in the first route. The reaction times were on the 
other hand longer in the second route. 
 
Despite of the convenience of the second route, the first one was found to be the most suitable 
for introducing diverse N-alkyl substituents. This is because the N-alkylation in the first route 
occurs in the second last step, and thus only two steps were needed for each different N-
alkylated analogue. In the second route the N-alkyl substituent was decided in the first step of 
the synthesis, making five steps necessary for each different N-alkylated analogue. Though, in 
the second route, the acylation with an acid chloride occurs in the last step, making this route 
more convergent for making analogues in which diversity in the arylamide moiety is desired. 
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The three prepared analogues 11, 13 and 15 will be submitted to biological testing in the near 
future. Depending on the results from these tests, future work on the development of new 
PPARδ antagonists will be evaluated. A suggestion for further modification of the GSK3787 
analogues, could be the substitution of the arylamide moiety (R1) (2-naphthyl in the herein 
prepared analogues 11, 13 and 15) with other groups (e.g. 6-quinolyl, 6-iso-quinolyl or 6-
fluoro-2-naphthyl, Figure 3.1). 
 
 
Figure 3.1: Suggested arylamide subtituents for future development of new PPARδ antagonists analogue 
to the GSK3787. 
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4 Spectroscopic elucidation and 
characterization of the compounds 
 
4.1 General remarks on the characterization of 
intermediates and analogues 
The prepared compounds consist, almost exclusively, of a common moiety (Figure 4.1), and 
some general characteristics in the recorded spectra of the compounds are noted here. 
Assigned spectra for each compound are found in the Appendix. 
 
Figure 4.1: Common moiety in the prepared compounds. 
 
The recorded 
1
H NMR spectra show signals as expected from the available literature for the 
aliphatic and aromatic protons [44]. The signal from H-7, next to the nitrogen atom in the 
pyridine ring, appears downfield from the aromatic region, because of the deshielding from 
both the nitrogen atom and the CF3-group. The signals from protons attached to N-10 in 
compounds where R1/R2 = H, vary from appearing as a triplet to a broad/narrow singlet 
around 6-8 ppm depending on solvents and concentration. 
 
In the 
13
C NMR, characteristic 
13
C - 
19
F splittings from the three fluorine atoms in the CF3-
group occur, and the C-1, C-2, C-3 and C-7 appear as quartets in the spectra. The C-1, closest 
to the fluorines, appears as a broad quartet (J = ~ 270 Hz) around 122.5 ppm, followed by C-
2, as a smaller quartet (J = ~ 35 Hz) around 130 ppm (Figure 4.2). C-3 and C-7 appear as 
narrow quartets (J = ~ 3.5 Hz) around 136 ppm and 147 ppm, respectively (Figure 4.3). 
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Figure 4.2: The splitting into quartets by fluorine in 
13
C NMR spectra. The quartet (J = ~ 270 Hz) around 
130 ppm belongs to C-1 and the quartet (J = ~ 35 Hz) around 122.5 ppm belongs to C-2. 
 
 
Figure 4.3: The splitting into quartets by fluorine in 
13
C NMR spectra. These two quartets (J = ~ 3.5) 
belong to C-3 and C-7 and appear around 136 ppm and 147 ppm, respectively. 
 
Due to this characteristic splitting of the carbon signals into quartets by fluorine, the intensity 
of the split signals becomes reduced, and in some spectra, the two outermost peaks in the 
quartets are not observable. Given the knowledge of the equidistance between the peaks of 
quartets in general [44], the coupling constants (J) of the quartets in the spectra in question, 
are calculated from the two observable peak values. 
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4.2 Observations of rotamers in the spectra of 
compounds 11, 13 and 15 
In the 
1
H NMR-spectra of compounds 11, 13 and 15, the signals from the aliphatic protons 
were broader than normal (Figure 4.4, Figure 4.5 and Figure 4.6). 
 
Figure 4.4: 
1
H NMR of the N-methyl analogue 11, showing broad signals (3.5 - 4.0 ppm) from the aliphatic 
protons in the molecule. 
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Figure 4.5: 
1
H NMR of the N-ethyl analogue 13, showing broad signals (3.5 - 4.0 ppm) from the aliphatic 
protons in the molecule. 
 
 
Figure 4.6: 
1
H NMR of the N-benzyl analogue 15, showing broad signals (3.5 - 4.0 ppm) from the aliphatic 
protons in the molecule. 
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The compounds 11, 13 and 15 carry alkyl substituents on their amide-nitrogens of the 
molecules. The structure of amides can be described with two resonance structures, of which 
the dominant one has a double bond between the carbonyl carbon and the amide nitrogen 
(Figure 4.7) [44]. 
 
Figure 4.7: The structure of amides described with two resonance structures [44]. 
 
Rotation about the C=N double bond is very slow and more energy demanding, thus 
hindering the free rotation of the amide substituents [44]. The exchange of the s-cis and s-
trans rotamers is sometimes observed in NMR spectroscopy when the barrier for rotation is 
sufficiently high, making the rotamers observable on NMR time scales [44]. 
 
In the NMR characterization of the final N-alkylated compounds 11, 13 and 15, we observed 
broader signals than normal for the aliphatic protons. This can be explained by the existence 
of rotamers. The N-H analogues did not show the same tendencies and rotamers were not 
observed until the insertion of the N-alkyl substituents. Interestingly, an N-methyl analogue 
with 4-fluorobenzyl as the arylamide moiety did not show rotamers in the spectra [41], as did 
the N-alkylated analogues with 2-naphthyl as the arylamide moiety. One explanation for this 
is probably the greater size and conformational behaviour of the 2-naphthyl group compared 
to the 4-fluorobenzyl group. This may cause a steric interaction with the N-alkyl group, that 
increases the energy barrier for exchange between the s-cis/s-trans rotamers, making them 
observable in the spectra. 
 
To test this hypothesis, we recorded 
1
H NMR-spectra of the N-benzyl analogue (15) at 
different temperatures, to see if the changes in the temperature would affect the speed of bond 
rotation in the molecule. The result show that as temperature increases, rotation speeds up and 
averages out the different rotameric conformations [44]. As we expected, coalescence of the 
aliphatic signals from the CH2-groups was observed with increasing temperature. 
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Figure 4.8: The aliphatic region in the 
1
H NMR-spectra recorded on the DPX200 instrument at 21 °C 
(bottom red line), 27 °C, 37 °C, 47 °C and 57 °C, for the N-benzyl analogue 15, showing coalescence of the 
signals from the CH2-groups (around 3.7 ppm) with increasing temperature. 
 
To further confirm that the poor 
1
H NMR spectra obtained at ambient temperature was not 
caused by impurities in the synthesis products, analytical HPLC was performed on the N-
benzyl analogue (15), confirming > 98% purity of the product. The chromatogram is shown in 
the Appendix (Figure 7.28). 
 
In the 
1
H NMR spectra of the second batch of compound 15, from the fifth approach, 
rotamers were also observable, further ensuring the rotamer hypothesis (Figure 4.9). 
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Figure 4.9: 
1
H NMR of the N-benzyl analogue 15 from the fifth approach, showing the same broad signals 
from the aliphatic protons (around 3.5 - 4.0 ppm) as in the spectra of the same compound (Figure 4.6), 
prepared by N-alkylation on the sulfide 9. 
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5 Experimental 
 
5.1 Materials and apparata 
All reagents and solvents were purchased from Sigma-Aldrich, Fluka or Merck, and used 
without further purification unless otherwise mentioned. Solutions were prepared prior to use 
and benzaldehyde was distilled prior to use. TLC silica gel 60 F254-plates from Merck, were 
used for thin-layer chromatography. Preparative chromatography was performed on silica gel 
60 (40-63 µm, Fluka). Inert gas-atmosphere (N2) and dry solvents were used in experiments 
with moisture and oxygen sensitive compounds. 
 
NMR spectra were recorded on Bruker Avance DPX-300 or Bruker Avance AVII-400 
spectrometers, operating at 300/400 MHz for 
1
H and 75/101 MHz for 
13
C, respectively. 
Spectra were recorded at 25 °C, unless otherwise noted. Coupling constants (J) are reported in 
hertz and chemical shift values (δ) in parts per million relative to the residual peaks for 
solvents used: 
1
H /
13C, δ7.26/ δ77.16 (CDCl3) and 
1
H/
13C, δ2.50/ δ39.52 (DMSO-d6). 
Analytical HPLC was performed on an Agilent 1200 series HPLC apparatus, with UV 
detection at 254 nm. Melting points were measured with a Stuart
TM
 melting point apparatus 
(SPM3) and are uncorrected. 
 
5.2 General experimental procedures 
 
5.2.1 General procedure for oxidation with potassium peroxymonosulfate 
triple salt (Oxone
TM
) 
To a stirred solution of the sulfide (1 eq) in water:acetone (1:4, 20 mL), potassium 
peroxymonosulfate triple salt (Oxone
TM
) (5 eq) was added and the reaction was stirred 
overnight. The acetone was removed under reduced pressure and the remaining suspension 
poured into water (40 mL) and extracted with EtOAc (2 x 40 mL). The combined extracts 
were washed with brine (40 mL) and dried over MgSO4. The solvent was removed under 
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reduced pressure. The remaining solid was purified with preparative chromatography using 
the same solvent system as for the reported Rf values, indicated in the specific procedures for 
each compound. 
 
5.2.2 General procedure for removal of Boc-protection groups 
The Boc-protected compound (1 eq) was added to a solution of HCl in dioxane (4 M, 22 mL) 
and stirred for 3 hours at ambient temperature. The reaction was diluted with Et2O (22 mL) 
and the resulting suspension was stirred for 10 minutes, before being filtered on a sintered 
glass funnel. The filter cake was washed with Et2O and the solid dried for 2 hours under high 
vacuum, affording the HCl-salt which was used without further purification. 
 
5.2.3 General procedure for the N-alkylation 
To a stirred solution of the sulfide (1 eq) in dry THF (7 mL) on ice, was added NaH (60% 
dispersion in mineral oil) (1.5 eq). After 10 minutes the alkyl halide (10 eq) was added and 
the reaction was stirred for 4 hours at 40 °C, quenched with a saturated solution of NaH2CO3 
(2 mL) and extracted with Et2O (30 mL). The extract was washed with brine (10 mL) and 
dried over MgSO4. The solvent was removed under reduced pressure and the remaining 
semisolid was solved in CH2Cl2 and filtered through a plug of silica. The solvent was 
removed under reduced pressure, affording an oil, which was used without further 
purification. 
 
5.3 Synthesis of intermediates 
 
5.3.1 Synthesis of tert-butyl(2-((5-(trifluoromethyl)pyridine-2-yl)thio)ethyl) 
carbamate (3) 
To a stirred solution of 5-(trifluoromethyl)mercaptopyridine (1) (1.03 g, 5.73 mmol) in dry 
DMF (20 mL) at ambient temperature, was added Et3N (2.00 mL, 14.38 mmol). After 5 
minutes a solution of 2-(N-Boc-amino)ethyl bromide (2) (1.38 g, 6.16 mmol) in dry DMF (10 
mL) was added and stirring was continued for 2 hours. The mixture was then poured into 
water (100 mL) and extracted with EtOAc (3 x 25 mL). The combined extracts were washed 
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with water (25 mL), brine (25 mL) and dried over MgSO4. The solvent was removed under 
reduced pressure, yielding a slightly yellow solid (1.69 g, 88%). By 
1
H NMR analysis the 
crude product was pure enough to be used without further purification. 
Physical data: 
1
H NMR (400 MHz, CDCl3) δ 8.63 (bs, 1H), 7.70 – 7.62 (m, 1H), 7.32 – 7.26 (m, 1H), 5.09 
(bs, 1H), 3.44 (t, J = 6.5 Hz, 2H), 3.33 (t, J = 6.3 Hz, 2H), 1.41 (s, 9H) 
13
C NMR (101 MHz, CDCl3) δ 163.56, 155.96, 146.29 (q, J = 4.3 Hz), 132.78 (q, J = 3.4 Hz), 
123.85 (q, J = 271.6 Hz), 122.57 (q, J = 33.2 Hz), 121.91, 79.51, 40.43, 30.19, 28.47 
Rf = 0.42 (1:4/EtOAc:hexane) 
Mp: 89 - 92 °C 
 
5.3.2 Synthesis of tert-butyl(2-((5-(trifluoromethyl)pyridine-2-yl)sulfonyl) 
ethyl)carbamate (4) 
The title compound was afforded as a colorless solid (1.11 g, 55%) from tert-butyl(2-((5-
(trifluoromethyl)pyridine-2-yl)thio)ethyl)carbamate (3) (1.69 g, 5.0 mmol) according to the 
general procedure for oxidation (Chapter 5.2.1). 
Physical data: 
1
H NMR (400 MHz, CDCl3) δ 8.99 (s, 1H), 8.29 – 8.19 (m, 2H), 5.13 (s, 1H), 3.85 – 3.47 (m, 
4H), 1.38 (s, 9H) 
13
C NMR (101 MHz, CDCl3) δ 160.67, 155.58, 147.38 (q, J = 3.9 Hz), 136.10 (q, J = 3.5 Hz), 
130.27 (q, J = 33.9 Hz), 122.56 (q, J = 273.3 Hz), 121.93, 80.12, 52.24, 34.73, 28.39 
Rf = 0.38 (40:60/EtOAc:hexane) 
Mp: 146 - 148 °C 
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5.3.3 Synthesis of 2-((5-(trifluoromethyl)pyridine-2-yl)sulfonyl) 
ethanaminium chloride (5) 
The title compound was afforded as a colorless solid (653 mg, 87%) from tert-butyl(2-((5-
(trifluoromethyl)pyridine-2-yl)sulfonyl)ethyl)carbamate (4) (909 mg, 2.57 mmol), according 
to the general procedure for removal of Boc-protection groups (Chapter 5.2.2). 
Physical data:  
1
H NMR (300 MHz, DMSO-d6) δ 9.44 – 9.17 (m, 1H), 8.66 (dd, J = 8.3, 2.3 Hz, 1H), 8.31 (d, 
J = 8.3 Hz, 1H), 8.22 (bs, 3H), 3.90 (t, 2H), 3.28 – 3.09 (m, 2H) 
Mp: 193 - 196 °C 
 
5.3.4 Synthesis of N-(2-((5-trifluoromethyl)pyridine-2-yl)sulfonyl)ethyl)2-
naphtamide (7) 
To a stirred solution of 2-((5-(trifluoromethyl)pyridine-2-yl)sulfonyl)ethanaminium chloride 
(5) (253 mg, 0.87 mmol) in dry THF (10 mL), was added Et3N (0.60 mL, 4.09 mmol). After 
10 minutes the reaction was cooled on ice, and 2-naphthoyl chloride (6) (383 mg, 2.00 mmol) 
was added drop wise. The reaction was stirred for 2 hours allowing the system to reach 
ambient temperature. The mixture was then poured into water (20 mL) and extracted with 
EtOAc (3 x 10 mL). The combined extracts were washed with saturated NH4Cl-solution (3 x 
10 mL), water (10 mL), brine (10 mL) and dried over MgSO4. The solvent was removed 
under reduced pressure and the remaining solid was purified with preparative chromatography 
(2 % MeOH in CH2Cl2) affording a colorless solid (222 mg, 63%). 
Physical data: 
1
H NMR (300 MHz, DMSO-d6) δ 9.08 – 9.02 (m, 1H), 8.65 (t, J = 5.3 Hz, 1H), 8.46 (dd, J = 
8.2, 1.7 Hz, 1H), 8.26 (d, J = 8.2 Hz, 1H), 8.18 (bs, 1H), 7.99 – 7.87 (m, 3H), 7.68 (dd, J = 
8.6, 1.7 Hz, 1H), 7.65 – 7.53 (m, 2H), 3.94 (t, J = 6.2 Hz, 2H), 3.71 (q, J = 6.0 Hz, 2H) 
13
C NMR (101 MHz, DMSO-d6) δ 165.96, 160.03, 147.17 (q, J = 4.0 Hz), 136.83 (q, J = 3.4 
Hz), 134.15, 131.90, 130.62, 128.74, 128.17 (q, J = 33.0 Hz), 127.73, 127.62, 127.51, 127.25, 
126.65, 123.59, 122.49 (q, J = 274.72 Hz), 122.17, 50.37, 33.86 
Rf = 0.41 (2 % MeOH in CH2Cl2) 
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Mp: 175 - 178 °C 
 
5.3.5 Synthesis of 2-((5-(trifluoromethyl)pyridine-2-yl)thio)ethanaminium 
chloride (8)  
The title compound was afforded as a colorless solid (1.13 g, 90%) from tert-butyl(2-((5-
(trifluoromethyl)pyridine-2-yl)thio)ethyl)carbamate (3) (1.65 g, 4.88 mmol) according to the 
general procedure for removal of Boc-protection groups (Chapter 5.2.2). 
Physical data: 
1
H NMR (300 MHz, DMSO-d6) δ 8.91 – 8.58 (m, 1H), 8.43 (bs, 3H), 8.01 (dd, J = 8.6, 2.4 
Hz, 1H), 7.62 (d, J = 8.5 Hz, 1H), 3.60 – 3.29 (m, 1H), 3.27 – 2.96 (m, 1H) 
13
C NMR (101 MHz, DMSO-d6) δ 162.75, 146.12 (q, J = 4.3 Hz), 133.65 (q, J = 3.4 Hz), 
123.88 (q, J = 271.8 Hz), 122.12, 121.51 (q, J = 32.7 Hz), 38.24, 26.59 
Mp: 215 - 220 °C 
 
5.3.6 Synthesis of 2-((5-(trifluoromethyl)pyridine-2-yl)thio)ethyl)-2-
naphtamide (9) 
To a stirred solution of 2-((5-(trifluoromethyl)pyridine-2-yl)thio)ethanaminium chloride (8) 
(346 mg, 1.34 mmol) in dry THF (10 mL), was added Et3N (1.2 mL, 6.29 mmol). After 10 
minutes the reaction was cooled on ice and 2-naphthoyl chloride (6) (656 mg, 3.44 mmol) was 
added drop wise. The reaction was stirred for 2 hours, allowing the system to reach ambient 
temperature. The mixture was then poured into water (20 mL) and extracted with EtOAc (3 x 
10 mL). The combined extracts were washed with saturated NH4Cl-solution (3 x 10 mL), 
water (10 mL), brine (10 mL) and dried over MgSO4. The solvent was removed under 
reduced pressure and the remaining solid was purified with preparative chromatography (1.5 
% MeOH in CH2Cl2) affording a colorless solid (303 mg, 60%). 
Physical data: 
1
H NMR (400 MHz, CDCl3) δ 8.79 – 8.69 (m, 1H), 8.25 (bs, 1H), 7.97 – 7.40 (m, 9H), 3.91 
(t, J = 6.3 Hz, 1H), 3.72 – 3.57 (m, 1H) 
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13
C NMR (101 MHz, CDCl3) δ 167.93, 164.07, 146.33 (q, J = 4.4 Hz), 134.88, 133.11 (q, J = 
3.1 Hz), 132.72, 131.82, 128.91, 128.51, 127.89, 127.78, 127.43, 126.90, 123.74 (q, J = 
276.74 Hz) 123.71, 123.04 (q, J = 33.5 Hz), 122.36, 41.16, 29.84 
Rf = 0.24 (1.5 % MeOH in CH2Cl2) 
Mp: 115 - 119 °C 
 
5.4  The first approach: direct amide N-alkylation of 
the sulfone 7 
 
5.4.1 Attempted synthesis of N-methyl-N-(2-((5-(trifluoromethyl)pyridine-
2-yl)sulfonyl)ethyl)-2-naphtamide (11) 
To a stirred solution of N-(2-((5-trifluoromethyl)pyridine-2-yl)sulfonyl)ethyl)-2-naphtamide 
(7) (100 mg, 0.25 mmol) in dry THF (4 mL), was added  a solution of t-BuOK (92 mg, 0.82 
mmol) in dry THF (2 mL). After 10 minutes MeI (0.10 mL, 1.61 mmol) was added and the 
reaction was stirred overnight at ambient temperature. The reaction was quenched with 
saturated NH4Cl-solution (2 mL), poured into water (20 mL), extracted with CH2Cl2 (2 x 40 
mL) and dried over MgSO4. The solvent was removed under reduced pressure and the 
remaining brown-yellow semisolid was purified with preparative chromatography. None of 
the separated products afforded the desired one. 
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5.5 The second approach: direct amide N-alkylation 
of the sulfide 9 
 
5.5.1 Synthesis of N-methyl-N-(2-((5-(trifluoromethyl)pyridine-2-yl)thio) 
ethyl)-2-naphtamide (10) 
The title compound was afforded as a colorless oil (324 mg) from 2-((5-
(trifluoromethyl)pyridine-2-yl)thio)ethyl)-2-naphtamide (9) (308 mg, 0.82 mmol) and MeI 
(0.50 mL, 8.03 mmol) according to the general procedure for N-alkylation (Chapter 5.2.3). 
Physical data: 
1
H NMR (400 MHz, DMSO-d6) δ 8.84 (s, 1H), 8.16 – 7.06 (m, 9H), 3.98 – 3.44 (m, 4H), 3.06 
(s, 3H) 
Rf = 0.20 (30:70/EtOAc:hexane) 
 
5.5.2 Synthesis of N-methyl-N-(2-((5-(trifluoromethyl)pyridine-2-yl) 
sulfonyl)ethyl)-2-naphtamide (11) 
The title compound was afforded as a colorless solid (186 mg, 43% yield over two steps) from 
N-methyl-N-(2-((5-(trifluoromethyl)pyridine-2-yl)thio)ethyl)-2-naftamide (10) (324 mg) 
according to the general procedure for oxidation (Chapter 5.2.1). 
Physical data: 
1
H NMR (400 MHz, CDCl3) δ 8.99 (s, 1H), 8.31 – 8.13 (m, 2H), 7.96 – 7.70 (m, 4H), 7.57 – 
7.33 (m, 3H), 4.13 – 3.53 (m, 4H), 3.10 (s, 3H) 
13
C NMR (101 MHz, CDCl3) δ 171.85, 160.35, 147.19 (m), 135.98 (m), 133.72, 132.79, 
132.56, 130.07 (q, J = 33.6 Hz), 128.42, 128.33, 127.81, 127.29, 127.01, 126.82, 124.07, 
122.88 (q, J = 275.73 Hz), 121.95, 49.38, 42.29, 38.82 
Rf = 0.37 (2 % MeOH in CH2Cl2) 
Mp: 121 - 123 °C 
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5.5.3 Synthesis of N-ethyl-N-(2-((5-(trifluoromethyl)pyridine-2-yl)thio) 
ethyl)-2-naphtamide (12) 
The title compound was afforded as a colorless oil (180 mg, 78%) from 2-((5-
(trifluoromethyl)pyridine-2-yl)thio)ethyl)-2-naftamide (9) (200 mg, 0.53 mmol) and EtI (0.40 
mL, 4.97 mmol) according to the general procedure for N-alkylation (Chapter 5.2.3). 
Physical data: 
1
H NMR (400 MHz, CDCl3) δ 8.68 (bs, 1H), 7.95 – 6.95 (m, 9H), 3.95 – 3.09 (m, 6H), 1.45 – 
1.05 (m, 3H) 
Rf = 0.23 (0.5% MeOH in CH2Cl2) 
 
5.5.4 Synthesis of N-ethyl-N-(2-((5-(trifluoromethyl)pyridine-2-yl) sulfonyl) 
ethyl)-2-naphtamide (13) 
The title compound was afforded as a colorless oil (114 mg, 59%) from N-ethyl-N-(2-((5-
(trifluoromethyl)pyridine-2-yl)thio)ethyl)-2-naphtamide (12) (180 mg, 0.41 mmol) according 
to the general procedure for oxidation (Chapter 5.2.1). 
Physical data: 
1
H NMR (400 MHz, CDCl3) δ 9.02 (s, 1H), 8.39 – 7.69 (m, 6H), 7.58 – 7.47 (m, 2H), 7.45 – 
7.33 (m, 1H), 4.10 – 3.67 (m, 4H), 3.59 – 3.31 (m, 2H), 1.16 (s, 3H) 
13
C NMR (101 MHz, CDCl3) δ 172.22, 160.55, 147.26 (m), 135.91 (q, J = 4.0 Hz), 133.69, 
133.28, 132.72, 130.18 (q, J = 33.9 Hz), 128.50, 128.44, 127.89, 127.26, 126.91, 126.31, 
122.78 (q, J = 274.72 Hz), 121.88, 60.45, 45.26, 39.42, 21.11 
Rf = 0.16 (30:70/EtOAc:hexane) 
 
5.5.5 Synthesis of N-benzyl-N-(2-((5-(trifluoromethyl)pyridine-2-yl)thio) 
ethyl)-2-naftamide (14) 
The title compound was afforded as a colorless oil (151 mg, 61%) from 2-((5-
(trifluoromethyl)pyridine-2-yl)thio)ethyl)-2-naftamide (9) (200 mg, 0.53 mmol) and BnBr 
(0.63 mL, 5.31 mmol) according to the general procedure for N-alkylation (Chapter 5.2.3), but 
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by adding TBAI (40 mg, 0.11 mmol) in addition to the other reagents. The temperature was 
increased to 50 °C instead of 40 °C. The purified product was used in the next step (oxidation) 
without characterization. 
Physical data: 
Rf = 0.4 (30:70/EtOAc:hexane) 
 
5.5.6 Synthesis of N-benzyl-N-(2-((5-(trifluoromethyl)pyridine-2-yl) 
sulfonyl)ethyl)-2-naphtamide (15) 
The title compound was afforded as a colorless crystals (69 mg, 65%) from N-benzyl-N-(2-
((5-(trifluoromethyl)pyridine-2-yl)thio)ethyl)-2-naphtamide (14) (150 mg, 0.32 mmol) 
according to the general procedure for oxidation (Chapter 5.2.1), with additional re-
crystallization from acetone:hexane to remove additional impurities. 
Physical data: 
1
H NMR (400 MHz, CDCl3) δ 8.97 (s, 1H), 8.34 – 7.10 (m, 14H), 4.73 (m, 2H), 4.08 – 3.37 
(m, 4H) 
13
C NMR (101 MHz, CDCl3) δ 172.43, 160.39, 147.18 (q, J = 3.6 Hz), 136.18 (q, J = 3.0 Hz), 
135.92, 133.74, 132.69, 132.61, 130.04 (q, J = 33.4 Hz), 129.53, 129.03, 128.56, 128.46, 
128.03, 127.82, 127.32, 127.17, 126.88, 123.93,122.42 (q, J = 272.7), 121.89, 77.32, 54.13, 
49.58, 39.67 
Rf = 0.31 (30:70/EtOAc:hexane) 
Mp: 148 - 150 °C 
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5.6 The third approach; direct amide N-alkylation of 
the carbamate 3 
 
5.6.1 The first attempt on synthesis of tert-butyl isopropyl(2-((5-
(trifluoromethyl)pyridin-2-yl)thio)ethyl)carbamate (16) 
The title compound was attempted to be afforded from 2-((5-(trifluoromethyl)pyridine-2-
yl)thio)ethyl) carbamate (3) (338 mg, 1.00 mmol) and i-PrBr (0.94 mL, 10.01 mmol) 
according to the general procedure for N-alkylation (Chapter 5.2.3), but by adding TBAI (74 
mg, 0.20 mmol) in addition to the other reagents. The reaction was stirred for 2 days at 
ambient temperature, instead of 4 hours at 40 °C, and was not filtered through a plug of silica. 
NMR of the crude product showed low yield of the desired product, and was not further 
purified or used in synthesis. 
 
5.6.2 The second attempt on synthesis of tert-butyl isopropyl(2-((5-
(trifluoromethyl)pyridin-2-yl)thio)ethyl)carbamate (16) 
The title compound was attempted to be afforded from 2-((5-(trifluoromethyl)pyridine-2-
yl)thio)ethyl) carbamate (3) (338 mg, 1.00 mmol) and i-PrBr (0.30 mL, 3.19 mmol) according 
to the general procedure for N-alkylation (Chapter 5.2.3), but by adding TBAI (1.19 g, 3.22 
mmol) and Cs2CO3 (999 mg, 3.07 mmol) in addition to the other reagents. The reaction was 
stirred for 1 day at ambient temperature, 1 day at 40 °C and 4 days at 50 °C, instead of 4 
hours at 40 °C. Additionally 3 eq. of i-PrBr was added to the reaction at day 5. Monitoring the 
reaction with TLC, showed no or a very low yield of any possible product, and the reaction 
was abandoned. 
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5.7 The fourth approach; the reductive amination 
route 
 
5.7.1 Synthesis of 2-(benzylamino)ethanol (19) 
To a stirred solution of benzaldehyde (17) (1.58 mL, 23.0 mmol) in methanol (100 mL) on 
ice, was added ethanolamine (18) (1.22 mL, 20.0 mmol) and stirring was continued for 7 
hours allowing the reaction to reach ambient temperature. The mixture was re-cooled on ice, 
and NaBH4 (1.74 g, 46.0 mmol) was added slowly. Stirring was continued overnight at 
ambient temperature and the reaction was quenched with HCl (6M) to pH 4. The solvent was 
removed under reduced pressure and the remaining aqueous suspension was poured into water 
(70 mL) and washed with CH2Cl2 (3 x 70 mL). The pH of the aqueous layer was adjusted 
with Na2CO3 (s) to pH 10, extracted with CH2Cl2 (2 x 60 mL) and the extracts were dried over 
MgSO4. The solvent was removed under reduced pressure to afford a colorless oil (2.00 g, 
66%), that by 
1
H NMR analyzes was pure enough to be used without further purification. 
Physical data: 
1
H NMR (400 MHz, CDCl3) δ 7.45 – 7.04 (m, 5H), 3.93 – 3.75 (m, 2H), 3.66 (t, 2H), 2.80 (t, 
2H), 2.46 (bs, 2H) 
 
5.7.2 Synthesis of tert-butyl benzyl(2-hydroxyethyl)carbamate (20) 
To a stirred solution of 2-(benzylamino)ethanol (19) (1.98 g, 13.08 mmol) in CH2Cl2 (45 mL) 
and NaOH (1 M, 35 mL), was added a solution of Boc2O (2.86 g, 13.08 mmol) in CH2Cl2 (50 
mL) slowly. The reaction was stirred overnight at ambient temperature, and the layers 
separated. The aqueous layer was extracted with CH2Cl2 (2 x 20 mL), the collected extracts 
washed with water (2 x 20 mL), brine (25 mL) and dried over Na2SO4. The solvent was 
removed under reduced pressure to afford a colorless oil (3.00 g, 93%), that by 
1
H NMR 
analyzes was pure enough to be used without further purification.  
Physical data: 
1
H NMR (400 MHz, CDCl3) δ 7.41 – 7.12 (m, 5H), 4.50 (m, 2H), 3.81 – 3.62 (m, 2H), 3.40 
(m, 2H), 2.58 (bs, 1H), 1.54 (s, 9H) 
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Rf = 0.22 (40:60/EtOAc:hexane) 
 
5.7.3 First attempt on synthesis of tert-butyl benzyl(2-
bromoethyl)carbamate (21) 
To a stirred solution of tert-butyl benzyl(2-hydroxyethyl)carbamate (20) (307 mg, 1.23 mmol) 
in CH2Cl2 (6 mL), was added PPh3 (402 mg, 1.53 mmol), CBr4 (601 mg, 1.81 mmol) and 
pyridine (0.16 mL, 2.04 mmol). The reaction was stirred for 1 hour, the suspension filtered 
and cold Et2O was added drop wise to the filtrate until precipitation of a colorless solid was 
observed. The resulting suspension was filtered, washed with cold Et2O (2 mL) and the 
solvent was removed under reduced pressure. This afforded a yellow semisolid that was 
purified with preparative chromatography, using 1-50% EtOAc in hexane, as the solvent 
system. The desired product could not be afforded, probably due to its invisibility on TLC 
plates when analyzing the fractions. 
 
5.7.4 Second attempt on synthesis of tert-butyl benzyl(2-
bromoethyl)carbamate (21) 
To a stirred solution of tert-butyl benzyl(2-hydroxyethyl)carbamate (20) (157 mg, 0.63 mmol) 
in CH2Cl2 (3 mL), was added PPh3 (206 mg, 0.78 mmol), CBr4 (304 mg, 0.92 mmol) and 
pyridine (0.08 mL, 1.02 mmol). The reaction was stirred for 2 hours, the solvent was removed 
under reduced pressure and the afforded colorless solid (206 mg) was used without further 
purification or characterization. 
 
5.7.5 Attempted synthesis of tert-butyl benzyl(2-((5-(trifluoromethyl) 
pyridine-2-yl)thio)ethyl) carbamate (23)  
To a stirred solution of the crude product from the synthesis of tert-butyl benzyl(2-
bromoethyl)carbamate (21) (206 mg) in dry DMF (4 mL), was added Et3N (0.25 mL, 1.8 
mmol) and 5-(trifluoromethyl)mercaptopyridine (1) (106 mg,
 
0.6 mmol) and the reaction was 
stirred overnight at ambient temperature. The mixture was poured into water (50 mL) and 
extracted with EtOAc (3 x 20 mL). The collected extracts were washed with water (20 mL), 
brine (20 mL) and dried over MgSO4. The solvent was removed under reduced pressure and 
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the remaining solid purified with preparative chromatography, affording a yellow oil (102 
mg). Due to significant amounts of impurities (probably triphenylphosphineoxide) in the 
1
H 
NMR-spectra, the purified product was not used in further synthesis. 
 
5.7.6 Synthesis of 2-(benzyl(tert-butoxycarbonyl)amino)ethyl methane 
sulfonate (22) 
To a stirred solution of tert-butyl benzyl(2-hydroxyethyl)carbamate (20) (308 mg, 1.2 mmol) 
in dry CH2Cl2 (5 mL) on ice, was added Et3N (0.18 mL, 1.32 mmol). Mesyl chloride (0.10 
mL, 1.32 mmol) was then added drop wise to the reaction and stirring was continued for 1 
hour at ambient temperature. The mixture was poured into brine (20 mL) and extracted with 
EtOAc (3 x 5 mL). The collected extracts were washed with a saturated solution of NaHCO3 
(2 x 5 mL), brine (2 x 5 mL) and dried over Na2SO4. The solvent was removed under reduced 
pressure and a yellow oil was afforded (345 mg, 88%), that showed one spot by TLC analysis. 
The crude product was used without further purification or characterization. 
Physical data: 
Rf= 0.2 (30:70/ EtOAc:hexane) 
 
5.7.7 Synthesis of tert-butyl benzyl(2-((5-(trifluoromethyl)pyridin-2-yl) 
thio)ethyl)carbamate (23) 
To a stirred solution of 2-(benzyl(tert-butoxycarbonyl)amino)ethyl methanesulfonate (22) 
(345 mg, 1.06 mmol) in dry DMF (6 mL), was added Et3N (0.42 mL, 3.02 mmol) and 5-
(trifluoromethyl)mercaptopyridine (1) (166 mg,
 
0.93 mmol) and the reaction was stirred 
overnight at ambient temperature. The mixture was poured into water (30 mL) and extracted 
with EtOAc (3 x 15 mL). The collected extracts were washed with brine (15 mL) and dried 
over MgSO4. The solvent was removed under reduced pressure and the remaining yellow oil 
was purified with preparative chromatography, that afforded a yellow oil (15 mg, 4%). 
1
H 
NMR data of the product (23) is found in Chapter 5.7.8 below, and is from the second 
synthesis of this compound. 
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5.7.8 “One-pot” synthesis of tert-butyl benzyl(2-((5-(trifluoromethyl) 
pyridine-2-yl)thio)ethyl) carbamate (23) 
To a stirred solution of tert-butyl benzyl(2-hydroxyethyl)carbamate (20) (302 mg, 1.21 mmol) 
in dry CH2Cl2 (6 mL) on ice, was added Et3N (0.35 mL, 2.52 mmol). Mesyl chloride (0.12 
mL, 1.44 mmol) was then added drop wise to the reaction and stirring was continued for 1 
hour at ambient temperature. Monitoring with TLC showed no spot for starting material and a 
possible spot for product. Another 2 eq. of Et3N (0.35 mL, 2.52 mmol) and a suspension of 5-
(trifluoromethyl) mercaptopyridine (1) (214 mg,
 
1.19 mmol) in dry CH2Cl2 (2 mL) was added 
to the reaction and stirring continued overnight. The mixture was poured into a saturated 
solution of Na2CO3 (40 mL) and extracted with EtOAc (3 x 25 mL). The collected extracts 
were washed with a saturated solution of Na2CO3 (2 x 25 mL), brine (25 mL) and dried over 
MgSO4. The solvent was removed under reduced pressure and the remaining semisolid (468 
mg) purified with preparative chromatography. This afforded a yellow oil (70 mg, 14%). 
Physical data: 
1
H NMR (400 MHz, CDCl3) δ 8.55 (bs, 1H), 7.57 (dd, J = 8.5, 2.3 Hz, 1H), 7.33 – 7.08 (m, 
6H), 4.61 – 4.32 (m, 2H), 3.50 – 3.33 (m, 2H), 3.33 – 3.13 (m, 2H), 1.40 (s, 9H) 
Rf= 0.24 (5:95/EtOAc:hexane) 
 
5.7.9  “One-pot” synthesis of tert-butyl benzyl(2-((5-(trifluoromethyl) 
pyridine-2-yl)thio)ethyl) carbamate (23) in the presence of NaI 
The title compound was attempted to be synthesized from tert-butyl benzyl(2-
hydroxyethyl)carbamate (20) (294 mg, 1.18 mmol), mesyl chloride (0.12 mL, 1.44 mmol) and 
5-(trifluoromethyl)mercaptopyridine (1) (217 mg,
 
1.20 mmol), according to the procedure for 
the second attempt on synthesis of the same compound (23), chapter 5.7.8, with the exception 
of addition of NaI (183 mg, 1.20 mmol) to the reaction. TLC showed very low yields of the 
desired product and the reaction was abandoned. 
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5.8 The fifth approach; acylation of a N-benzyl HCl-
salt (29) 
 
5.8.1 N-benzyl-N-(2-((5-(trifluoromethyl)pyridine-2-yl)sulfonyl)) 
ethanaminium chloride (29) 
Synthesis of 29 was performed by Ph. D. student Åsmund Kaupang according to Scheme 2.11 
and experimental details is not reported here. 
Physical data: 
1
H NMR (400 MHz, DMSO-d6) δ 9.89 (bs, 2H), 9.26 (s, 1H), 8.66 (dd, J = 8.3, 2.3 Hz, 1H), 
8.31 (d, J = 8.2 Hz, 1H), 7.61 – 7.47 (m, 2H), 7.46 – 7.24 (m, 3H), 4.17 (s, 2H), 4.14 – 4.04 
(m, 2H), 3.42 – 3.20 (m, 2H) 
13
C NMR (101 MHz, DMSO-d6) δ 159.03, 147.57 (q, J = 3.9 Hz), 137.44 (q, J = 3.6 Hz), 
131.76, 129.99, 128.93, 128.87 (q, J = 33.1 Hz), 128.62, 122.73 (q, J = 273.5 Hz), 122.49, 
49.71, 47.83, 39.60 
 
5.8.2 Synthesis of N-benzyl-N-(2-((5-(trifluoromethyl)pyridine-2-yl) 
sulfonyl)ethyl)-2-naphtamide (15) 
To a stirred solution of N-benzyl-N-(2-((5-(trifluoromethyl)pyridine-2-yl)sulfonyl)) 
ethanaminium chloride (29) (89 mg, 0.24 mmol) in dry THF (5 mL), was added Et3N (0.17 
mL, 1.13 mmol). After 10 minutes the reaction was cooled on ice and 2-naphthoyl chloride 
(6) (91 mg, 0.47 mmol) was added drop wise. The reaction was stirred for 5 hours, allowing 
the system to reach ambient temperature. The mixture was then poured into saturated solution 
of Na2CO3 (10 mL) and extracted with EtOAc (3 x 5 mL). The combined extracts were 
washed with a saturated solution of Na2CO3 (3 x 10 mL), brine (10 mL) and dried over 
MgSO4. The solvent was removed under reduced pressure and the remaining solid was 
purified with preparative chromatography affording a colorless solid (98 mg, 84%). 
Physical data: 
1
H NMR (300 MHz, CDCl3) δ 8.98 (bs, 1H), 8.40 – 7.07 (m, 14H), 4.94 – 4.53 (m, 2H), 4.03 
– 3.42 (m, 4H) 
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Rf = 0.3 (20:80/EtOAc:hexane)  
Mp: 149 - 151 °C 
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7 Appendix 
 
7.1 Intermediates 
 
7.1.1 1H NMR, 13C NMR, DEPT and HMQC of tert-butyl(2-((5-
(trifluoromethyl)pyridine-2-yl)thio)ethyl)carbamate (3) 
 
 
Figure 7.1: 
1
H NMR spectrum of compound (3). 
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Figure 7.2: 
13
C NMR spectrum of compound (3). 
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Figure 7.3: DEPT spectrum of compound (3). 
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Figure 7.4: HMQC spectrum of compound (3). 
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7.1.2 1H NMR, 13C NMR and DEPT of tert-butyl(2-((5-(trifluoromethyl) 
pyridine-2-yl)sulfonyl)ethyl)carbamate (4) 
 
 
Figure 7.5: 
1
H NMR spectrum of compound (4). 
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Figure 7.6: 
13
C NMR spectrum of compound (4). 
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Figure 7.7: DEPT spectrum of compound (4). 
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7.1.3 1H NMR of 2-((5-(trifluoromethyl)pyridine-2-yl)sulfonyl) 
ethanaminium chloride (5) 
 
 
Figure 7.8: 
1
H NMR spectrum of compound (5). 
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7.1.4 1H NMR, 13C NMR and DEPT of N-(2-((5-trifluoromethyl)pyridine-2-
yl)sulfonyl)ethyl)2-naphtamide (7) 
 
 
Figure 7.9: 
1
H NMR spectrum of compound (7). 
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Figure 7.10: 
13
C NMR spectrum of compound (7). 
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Figure 7.11: DEPT spectrum of compound (7). 
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7.1.5 1H NMR, 13C NMR and DEPT of 2-((5-(trifluoromethyl)pyridine-2-
yl)thio)ethanaminium chloride (8) 
 
 
Figure 7.12: 
1
H NMR spectrum of compound (8). 
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Figure 7.13: 
13
C NMR spectrum of compound (8). 
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Figure 7.14: DEPT spectrum of compound (8). 
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7.1.6 1H NMR and 13C NMR of 2-((5-(trifluoromethyl)pyridine-2-
yl)thio)ethyl)-2-naftamide (9) 
 
 
Figure 7.15: 
1
H NMR spectrum of compound (9). 
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Figure 7.16: 
13
C NMR spectrum of compound (9). 
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7.2 N-alkylated intermediates and analogues 
 
7.2.1 1H NMR of N-methyl-N-(2-((5-(trifluoromethyl)pyridine-2-yl) 
sulfonyl)ethyl)-2-naftamide (10) 
 
 
Figure 7.17: 
1
H NMR spectrum of compound (10). 
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7.2.2 1H NMR, 13C NMR and DEPT of N-methyl-N-(2-((5-
(trifluoromethyl)pyridine-2-yl)sulfonyl)ethyl)-2-naftamide (11)  
 
 
Figure 7.18: 
1
H NMR spectrum of compound (11). 
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Figure 7.19: 
13
C NMR spectrum of compound (11). 
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Figure 7.20: DEPT spectrum of compound (11). 
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7.2.3 1H NMR of N-ethyl-N-(2-((5-(trifluoromethyl)pyridine-2-yl)thio) 
ethyl)-2-naftamide (12) 
 
 
Figure 7.21: 
1
H NMR spectrum of compound (12). 
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7.2.4 1H NMR, 13C NMR and DEPT of N-ethyl-N-(2-((5-(trifluoromethyl) 
pyridine-2-yl)sulfonyl)ethyl)-2-naftamide (13) 
 
 
Figure 7.22: 
1
H NMR spectrum of compound (13). 
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Figure 7.23: 
13
C NMR spectrum of compound (13). 
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Figure 7.24: DEPT spectrum of compound (13). 
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7.2.5 1H NMR, 13C NMR, DEPT and HPLC of N-benzyl-N-(2-((5-
(trifluoromethyl) pyridine-2-yl)sulfonyl)ethyl)-2-naftamide (15) 
 
 
Figure 7.25: 
1
H NMR spectrum of compound (15). 
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Figure 7.26: 
13
C NMR spectrum of compound (15). 
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Figure 7.27: DEPT spectrum of compound (15). 
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Figure 7.28: HPLC chromatogram of compound (15) 
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7.2.6 1H NMR and 13C NMR of N-benzyl-N-(2-((5-
(trifluoromethyl)pyridine-2-yl) sulfonyl))ethanaminium chloride (29) 
 
 
Figure 7.29: 
1
H NMR spectrum of compound (29). 
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Figure 7.30: 
13
C NMR spectrum of compound (29). 
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7.2.7 1H NMR of N-benzyl-N-(2-((5-(trifluoromethyl)pyridine-2-yl) 
sulfonyl)ethyl)-2-naftamide (15) from the fifth approach 
 
 
Figure 7.31: 
1
H NMR spectrum of compound (15). 
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7.3 Intermediates from the attempted synthesis 
 
7.3.1 1H NMR of 2-(benzylamino)ethanol (19) 
 
 
Figure 7.32: 
1
H NMR spectrum of compound (19). 
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7.3.2 1H NMR of tert-butyl benzyl(2-hydroxyethyl)carbamate (20) 
 
 
Figure 7.33: 
1
H NMR spectrum of compound (20). 
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7.3.3 1H NMR of tert-butyl benzyl(2-((5-(trifluoromethyl)pyridine-2-yl) 
thio)ethyl)carbamate (23) 
 
 
Figure 7.34: 
1
H NMR spectrum of compound (23). 
 
 
 
